title: A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
abstract: OBJECTIVE
  To define the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), the biological active (BA) dose and the pharmacokinetics (PK) of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa) when administered continuously as a once daily dose in patients with advanced, incurable solid tumours.
  
  
  METHODS
  Twenty-eight patients were enrolled in cohorts of three from three National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) centers. ZD1839 was given at doses from 150 to 800 mg daily orally and patients underwent a pretreatment and a 28 day post treatment tumor biopsy, while PK sampling was performed on days 8, 15, 22, 29, and a toxicity assessment every 28 days.
  
  
  RESULTS
  All twenty-eight patients were evaluable for non-hematological and hematological toxicity. Twenty-seven were evaluable for response. The MTD was not reached but DLT included reversible rash and diarrhea. One patient with urachal cancer had a transient 55% decrease in tumor size and two other patients (breast and non-small cell lung cancer) had minor responses; three additional patients had pharmacodynamic evidence of target effect. PK demonstrated steady state within the first 2 weeks of dosing and dose dependent exposure.
  
  
  CONCLUSIONS
  It appears that ZD 1839 at a dose of 800 m/day was tolerable, although some patients required dose modification for diarrhea. Doses above 250 m/day demonstrate biologic activity and could be consider for future study in a variety of EGFR positive tumor types.
authors.affiliation: Ottawa Regional Cancer Centre, Ottawa, Ontario K1H 1C4, Canada. glenwood.goss@orcc.on.ca
authors.forename: G
authors.initials: G
authors.lastname: Goss
authors.forename: H
authors.initials: H
authors.lastname: Hirte
authors.forename: W H
authors.initials: WH
authors.lastname: Miller
authors.forename: I A J
authors.initials: IA
authors.lastname: Lorimer
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: G
authors.initials: G
authors.lastname: Batist
authors.forename: D A E
authors.initials: DA
authors.lastname: Parolin
authors.forename: P
authors.initials: P
authors.lastname: Hanna
authors.forename: S
authors.initials: S
authors.lastname: Stafford
authors.forename: J
authors.initials: J
authors.lastname: Friedmann
authors.forename: W
authors.initials: W
authors.lastname: Walsh
authors.forename: S
authors.initials: S
authors.lastname: Mathews
authors.forename: L
authors.initials: L
authors.lastname: Douglas
authors.forename: L K
authors.initials: LK
authors.lastname: Seymour
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D002170:Canada; D066246:ErbB Receptors / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D000077156:Gefitinib; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib
references.citation: Clin Cancer Res. 2000 Dec;6(12):4885-92
references.pmid: 11156248
references.citation: Arch Surg. 1986 Nov;121(11):1242-7
references.pmid: 3535739
references.citation: J Clin Oncol. 2002 May 1;20(9):2240-50
references.pmid: 11980995
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4292-302
references.pmid: 12409327
references.citation: Int J Radiat Oncol Biol Phys. 1992;22(1):225-30
references.pmid: 1309204
references.citation: J Biol Chem. 1994 Jan 7;269(1):260-5
references.pmid: 8276804
references.citation: J Biol Chem. 1992 Feb 5;267(4):2714-22
references.pmid: 1733967
references.citation: Cancer Res. 1995 Dec 1;55(23):5536-9
references.pmid: 7585629
references.citation: Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):657-66
references.pmid: 8824370
references.citation: J Biol Chem. 1998 Jan 2;273(1):200-6
references.pmid: 9417065
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Clin Pharmacokinet. 2001;40(4):297-306
references.pmid: 11368294
references.citation: Jpn J Cancer Res. 1985 Aug;76(8):663-6
references.pmid: 2995289
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: J Biol Chem. 1991 Nov 15;266(32):22035-43
references.pmid: 1657987
references.citation: Ann Oncol. 1997 Dec;8(12):1197-206
references.pmid: 9496384
references.citation: Br J Cancer. 1986 Aug;54(2):265-9
references.pmid: 3017396
references.citation: Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47
references.pmid: 10758303
references.citation: Proc Natl Acad Sci U S A. 1998 May 12;95(10):5724-9
references.pmid: 9576951
references.citation: Bioorg Med Chem Lett. 2001 Jul 23;11(14):1911-4
references.pmid: 11459659
references.citation: J Pharm Biomed Anal. 2002 Jun 20;29(1-2):221-8
references.pmid: 12062681
references.citation: Oncogene. 1994 Aug;9(8):2313-20
references.pmid: 8036013
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3815-25
references.pmid: 12228201
references.citation: Growth Factors. 1991;4(4):305-16
references.pmid: 1722417